A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

Trial ID or NCT#

NCT02428712

Status

not recruiting iconNOT RECRUITING

Purpose

The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of FORE8394.

Official Title

A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of FORE8394 in Patients With Advanced Unresectable Solid Tumors

Eligibility Criteria

Ages Eligible for Study: Older than 10 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Sunil Arani Reddy
Sunil Arani Reddy
Medical oncologist, Cutaneous oncology specialist
Clinical Associate Professor, Medicine - Oncology

Contact us to find out if this trial is right for you.

Contact

CCTO
650-498-7061

View on ClinicalTrials.gov